Table. Recommendations for immunisation of infants and children aged <2 years using meningococcal ACWY vaccines, by age and vaccine brand
Medical conditions are specified in List. Specified medical conditions associated with increased risk of invasive meningococcal disease.
|
Age at start of vaccine course |
MenACWY vaccine brand |
Dose requirements for healthy people (without any medical conditions associated with increased risk of invasive meningococcal disease) |
|
6 weeks to 5 months |
Menveo Nimenrix |
3 doses (8 weeks between 1st and 2nd doses; 3rd dose at 12 months of age) |
|
6–8 months |
Menveo Nimenrix |
2 doses (2nd dose at 12 months of age or 8 weeks after 1st dose, whichever is later) |
|
9–11 months |
Menveo Nimenrix Menactra |
2 doses (2nd dose at 12 months of age or 8 weeks after 1st dose, whichever is later) |
|
12–23 months |
Menveo |
2 doses (8 weeks between doses) |
|
Nimenrix |
1 dose |
|
|
Menactra |
2 doses (8 weeks between doses) |
Table. Recognition and treatment of anaphylaxis
Table. Recommendations for immunisation of infants and children aged
Printed content may be out of date. For up to date information, always refer to the digital version: https://immunisationhandbook.health.gov.au/resources/handbook-tables/table-recommendations-for-immunisation-of-infants-and-children-aged.